Sarika Mehra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarika Mehra has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Shou Hu
Department of Chemical Engineering and Materials Science University of Minnesota Minneapolis Minnesota USA
7 shared publications - Rajdip Bandyopadhyaya
Indian Institute of Technology Bombay Powai
6 shared publications Deepika Rai
Department of Chemical Engineering, Indian Institute of Technology Bombay
4 shared publications- Vikas Chandrawanshi
Department of Chemical Engineering , Indian Institute of Technology Bombay , Mumbai , India 400076
4 shared publications Ankita Nag
Indian Institute of Technology Bombay
3 shared publicationsMinal Patkari
Department of Chemical Engineering, IIT Bombay, Powai, 400076, India
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (11) , e0006539
Predictors of treatment outcomes in adults with drug–sensitive Tuberculosis in Maharashtra, India: A retrospective study
Tuberculosis (TB) remains the leading infectious cause of death worldwide, with India accounting for nearly one-fourth of global TB cases. Ni-kshay, the country’s digital case-based TB notification platform is rich in data pertaining to the continuum of care of TB patients. This study aims to develop a standardized analytical approach to programmatic data to identify predictors of unfavourable treatment outcomes and mortality among adult drug-sensitive TB patients at the state level for Maharashtra during 2021 and 2022. Two separate analyses were undertaken comparing treatment success with: (1) unfavourable outcomes (death, treatment failure, loss to follow-up, regimen change, or not evaluated); and (2) mortality. Age group, gender and pre-treatment weight were entered together in a single logistic regression model, and each remaining risk factor was entered into a separate model alongside those three covariates, to compute adjusted odds ratios (aOR). Records with no entry for diabetes, HIV, tobacco or alcohol were retained as a “not recorded” or “unknown” category. Collinearity across variables was assessed using Cramer’s V and variance inflation factors. The final cohort included 323,124 cases for unfavourable outcome analysis and 315,579 cases for mortality analysis. Increasing age, male gender, lower body weight, known HIV and diabetes comorbidities, tobacco and alcohol consumption, and “unknown” status for behavioural risks and comorbidity status were significantly associated with increased odds of both unfavourable outcomes and mortality. This study highlights the utility of programmatic data in identifying high-risk TB patients and offers a reproducible analytic framework.
- 6 November 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (11) , e0006539
Open AccessPredictors of treatment outcomes in adults with drug–sensitive Tuberculosis in Maharashtra, India: A retrospective study
Tuberculosis (TB) remains the leading infectious cause of death worldwide, with India accounting for nearly one-fourth of global TB cases. Ni-kshay, the country’s digital case-based TB notification platform is rich in data pertaining to the continuum of care of TB patients. This study aims to develop a standardized analytical approach to programmatic data to identify predictors of unfavourable treatment outcomes and mortality among adult drug-sensitive TB patients at the state level for Maharashtra during 2021 and 2022. Two separate analyses were undertaken comparing treatment success with: (1) unfavourable outcomes (death, treatment failure, loss to follow-up, regimen change, or not evaluated); and (2) mortality. Age group, gender and pre-treatment weight were entered together in a single logistic regression model, and each remaining risk factor was entered into a separate model alongside those three covariates, to compute adjusted odds ratios (aOR). Records with no entry for diabetes, HIV, tobacco or alcohol were retained as a “not recorded” or “unknown” category. Collinearity across variables was assessed using Cramer’s V and variance inflation factors. The final cohort included 323,124 cases for unfavourable outcome analysis and 315,579 cases for mortality analysis. Increasing age, male gender, lower body weight, known HIV and diabetes comorbidities, tobacco and alcohol consumption, and “unknown” status for behavioural risks and comorbidity status were significantly associated with increased odds of both unfavourable outcomes and mortality. This study highlights the utility of programmatic data in identifying high-risk TB patients and offers a reproducible analytic framework.
- Open Access
- 12 September 2026
- Published by Springer Nature in npj Systems Biology and Applications
Comparative transcriptomic analysis reveals distinct ER stress responses in tunicamycin sensitive and resistant CHO cells
- 12 September 2026
- Published by Springer Nature in npj Systems Biology and Applications
Open AccessComparative transcriptomic analysis reveals distinct ER stress responses in tunicamycin sensitive and resistant CHO cells
- Open Access
Assessing the Impact of Interventions on Tuberculosis Control: India Based Modelling Framework
Background: India accounts for nearly one-fourth of the global tuberculosis (TB) burden. The country’s progress towards elimination of TB is hindered by considerable heterogeneity in behavioural, social, and health system determinants, which influence transmission dynamics and care access. Evidence from the recent national TB prevalence survey showed that almost half of individuals with active disease were asymptomatic, underscoring the limitations of symptom-based case finding. Achieving the End TB targets will therefore require strategies that simultaneously address the substantial pool of individuals with undiagnosed, asymptomatic disease and those symptomatic individuals who do not seek care. Methods: We developed a transmission model of TB that explicitly incorporates individuals with asymptomatic disease, and those who do not seek care. Model calibration was performed within a Bayesian framework using epidemiological and programmatic data for India. The calibrated model was then used to project the potential impact of intervention on TB incidence and mortality. Results: Under the baseline scenario, the estimated TB incidence and mortality rates for 2024 were 180 (163-203) and 24 (18–31) per 100,000 population, respectively. Across all intervention scenarios targeting improved diagnosis, active case finding, nutrition support and their combination the reduction in incidence rate by 2030 ranged from 13% to 60% compared with 2025, while the corresponding decline in mortality rate ranged from 16% to 66%. Conclusion: While individual interventions yield measurable reductions in TB incidence and mortality, but greater impact is achieved when implemented in combination reflecting the need for a comprehensive, multi-component response towards TB elimination. What is already known on this topic: Studies have analysed the impact of single intervention scenarios across different regions and India What this study adds: We developed a dynamic model of tuberculosis in India, modelling the impact of four different interventions: nutritional support, health facility improvements, active case finding and a combination of all three. We found that a single intervention cannot be considered powerful enough to improve the rate of decline of incidence and mortality and so a multi-sectoral intervention scenario is required. How this study might affect research, practice or policy: Accelerating the decline in tuberculosis burden requires interventions targeting the entire care cascade while simultaneously providing nutritional support.
Open AccessAssessing the Impact of Interventions on Tuberculosis Control: India Based Modelling Framework
Background: India accounts for nearly one-fourth of the global tuberculosis (TB) burden. The country’s progress towards elimination of TB is hindered by considerable heterogeneity in behavioural, social, and health system determinants, which influence transmission dynamics and care access. Evidence from the recent national TB prevalence survey showed that almost half of individuals with active disease were asymptomatic, underscoring the limitations of symptom-based case finding. Achieving the End TB targets will therefore require strategies that simultaneously address the substantial pool of individuals with undiagnosed, asymptomatic disease and those symptomatic individuals who do not seek care. Methods: We developed a transmission model of TB that explicitly incorporates individuals with asymptomatic disease, and those who do not seek care. Model calibration was performed within a Bayesian framework using epidemiological and programmatic data for India. The calibrated model was then used to project the potential impact of intervention on TB incidence and mortality. Results: Under the baseline scenario, the estimated TB incidence and mortality rates for 2024 were 180 (163-203) and 24 (18–31) per 100,000 population, respectively. Across all intervention scenarios targeting improved diagnosis, active case finding, nutrition support and their combination the reduction in incidence rate by 2030 ranged from 13% to 60% compared with 2025, while the corresponding decline in mortality rate ranged from 16% to 66%. Conclusion: While individual interventions yield measurable reductions in TB incidence and mortality, but greater impact is achieved when implemented in combination reflecting the need for a comprehensive, multi-component response towards TB elimination. What is already known on this topic: Studies have analysed the impact of single intervention scenarios across different regions and India What this study adds: We developed a dynamic model of tuberculosis in India, modelling the impact of four different interventions: nutritional support, health facility improvements, active case finding and a combination of all three. We found that a single intervention cannot be considered powerful enough to improve the rate of decline of incidence and mortality and so a multi-sectoral intervention scenario is required. How this study might affect research, practice or policy: Accelerating the decline in tuberculosis burden requires interventions targeting the entire care cascade while simultaneously providing nutritional support.
- Open Access
Predictors of treatment outcomes in adults with drug–sensitive Tuberculosis in Maharashtra, India: A retrospective study
Background: Tuberculosis (TB) remains the leading infectious cause of death worldwide, with India accounting for nearly one-fourth of global TB cases. Ni-kshay, the country’s digital case-based TB notification platform is rich in data pertaining to the continuum of care of TB patients. This study aims to develop a standardized analytical approach to programmatic data to identify predictors of unfavourable treatment outcomes and mortality among adult drug-sensitive TB patients at the state level for Maharashtra during 2021 and 2022. Methods: Two separate analyses were undertaken comparing treatment success with: (1) unfavourable outcomes (death, treatment failure, loss to follow-up, regimen change, or not evaluated); and (2) mortality. Multivariate logistic regression was used to compute adjusted odds ratios (aOR) for key risk factors, adjusting for age, gender, and weight. Results: The final cohort included 323,124 cases for unfavourable outcome analysis and 315,579 cases for mortality analysis. Increasing age, male gender, lower body weight, known HIV and diabetes comorbidities, tobacco and alcohol consumption, and "unknown" status for behavioural risks and comorbidity status were significantly associated with increased odds of both unfavourable outcomes and mortality. Conclusions: This study highlights the utility of programmatic data in identifying high-risk TB patients and offers a reproducible analytic framework.
Open AccessPredictors of treatment outcomes in adults with drug–sensitive Tuberculosis in Maharashtra, India: A retrospective study
Background: Tuberculosis (TB) remains the leading infectious cause of death worldwide, with India accounting for nearly one-fourth of global TB cases. Ni-kshay, the country’s digital case-based TB notification platform is rich in data pertaining to the continuum of care of TB patients. This study aims to develop a standardized analytical approach to programmatic data to identify predictors of unfavourable treatment outcomes and mortality among adult drug-sensitive TB patients at the state level for Maharashtra during 2021 and 2022. Methods: Two separate analyses were undertaken comparing treatment success with: (1) unfavourable outcomes (death, treatment failure, loss to follow-up, regimen change, or not evaluated); and (2) mortality. Multivariate logistic regression was used to compute adjusted odds ratios (aOR) for key risk factors, adjusting for age, gender, and weight. Results: The final cohort included 323,124 cases for unfavourable outcome analysis and 315,579 cases for mortality analysis. Increasing age, male gender, lower body weight, known HIV and diabetes comorbidities, tobacco and alcohol consumption, and "unknown" status for behavioural risks and comorbidity status were significantly associated with increased odds of both unfavourable outcomes and mortality. Conclusions: This study highlights the utility of programmatic data in identifying high-risk TB patients and offers a reproducible analytic framework.
- Open Access
Efflux pump regulation and metabolic rewiring define the ceiling of efflux-mediated drug resistance in Mycobacteria
Multidrug-resistant efflux pumps play a critical role in antimicrobial resistance, yet the physiological limits of their overexpression remain poorly understood. While gene amplifications and regulatory mutations commonly drive this overexpression, these pumps remain transcriptionally inactive under normal cellular conditions due to their high energetic cost, making it challenging to assess their full impact on resistance evolution and the maximum attainable minimum inhibitory concentration (MIC). To delineate the extent and spectrum of efflux-based resistance, we subjected Mycobacterium smegmatis mc²155(Msm) wild-type and efflux pump-deleted strains (Δ lfrA and Δ efpA ) to adaptive laboratory evolution in the presence of a broad-spectrum efflux substrate ethidium bromide (EtBr). Despite prolonged selection, resistance plateaued at 8–16× MIC, revealing an intrinsic ceiling to efflux-based adaptation. Evolved populations integrated multiple layers of adaptation: enhanced efflux kinetics, reduced intracellular EtBr accumulation, and mutations spanning global regulators, ribosomal genes, and membrane components. Notably, deletion of specific pumps (Δ lfrA) triggered compensatory upregulation of alternative efflux systems, highlighting functional redundancy. Beyond efflux activation, evolved strains exhibited metabolic reprogramming, including downregulation of the tricarboxylic acid cycle and upregulation of lipid biosynthesis and β-oxidation, which altered NAD+/NADH homeostasis and membrane potential. Extending this adaptive evolution approach to Mycobacterium tuberculosis H37Ra ( Mtb) demonstrated that these adaptive constraints and metabolic alterations are conserved across mycobacterial species. Together, these results uncover fundamental limits to efflux evolution and reveal how bacteria integrate regulatory and metabolic plasticity to maximize drug resistance. Targeting these interconnected networks may offer a powerful strategy to contain the rise of multidrug resistance.
Open AccessEfflux pump regulation and metabolic rewiring define the ceiling of efflux-mediated drug resistance in Mycobacteria
Multidrug-resistant efflux pumps play a critical role in antimicrobial resistance, yet the physiological limits of their overexpression remain poorly understood. While gene amplifications and regulatory mutations commonly drive this overexpression, these pumps remain transcriptionally inactive under normal cellular conditions due to their high energetic cost, making it challenging to assess their full impact on resistance evolution and the maximum attainable minimum inhibitory concentration (MIC). To delineate the extent and spectrum of efflux-based resistance, we subjected Mycobacterium smegmatis mc²155(Msm) wild-type and efflux pump-deleted strains (Δ lfrA and Δ efpA ) to adaptive laboratory evolution in the presence of a broad-spectrum efflux substrate ethidium bromide (EtBr). Despite prolonged selection, resistance plateaued at 8–16× MIC, revealing an intrinsic ceiling to efflux-based adaptation. Evolved populations integrated multiple layers of adaptation: enhanced efflux kinetics, reduced intracellular EtBr accumulation, and mutations spanning global regulators, ribosomal genes, and membrane components. Notably, deletion of specific pumps (Δ lfrA) triggered compensatory upregulation of alternative efflux systems, highlighting functional redundancy. Beyond efflux activation, evolved strains exhibited metabolic reprogramming, including downregulation of the tricarboxylic acid cycle and upregulation of lipid biosynthesis and β-oxidation, which altered NAD+/NADH homeostasis and membrane potential. Extending this adaptive evolution approach to Mycobacterium tuberculosis H37Ra ( Mtb) demonstrated that these adaptive constraints and metabolic alterations are conserved across mycobacterial species. Together, these results uncover fundamental limits to efflux evolution and reveal how bacteria integrate regulatory and metabolic plasticity to maximize drug resistance. Targeting these interconnected networks may offer a powerful strategy to contain the rise of multidrug resistance.
- Open Access
Adaptive Laboratory Evolution under gradual ciprofloxacin stress leads to efflux-mediated ciprofloxacin resistance and an increase in endogenous antibiotic production in Streptomyces coelicolor
Streptomyces are soil-dwelling bacteria harboring a vast reservoir of transcriptionally silent antibiotic-resistant genes. Mobilization of these resistance genes to pathogens results in the dissemination of multidrug resistance when exposed to differential antibiotic pressure. To determine the evolution of resistance, we employed adaptive laboratory evolution (ALE) in Streptomyces coelicolor under gradually increasing concentrations of ciprofloxacin, starting at the minimum inhibitory concentration (MIC) to 4X MIC. The evolved strain CipRr exhibited elevated resistance towards ciprofloxacin with cross-resistance to other fluoroquinolones, such as ofloxacin and moxifloxacin, and collateral sensitivity to the protein synthesis inhibitors chloramphenicol and tetracycline. Compared to the WT cells, CipRr showed elevated production of secondary metabolites actinorhodin and undecylprodigiosin, altered morphology, and reduced ROS production. Whole Genome Sequencing revealed mutations in transcriptional regulators and other metabolic genes, leading to enhanced activity of efflux pumps that conferred high-level ciprofloxacin resistance. Overall, this study demonstrates that evolutionary strategies in antibiotic producers such as streptomyces can help uncover the genetic determinants linked to antibiotic resistance, secondary metabolism, and morphological differentiation. Importance: This study employs adaptive laboratory evolution in the antibiotic-producing bacterium Streptomyces coelicolor to investigate how exposure to gradually increasing concentrations of the fluoroquinolone ciprofloxacin drives the emergence of high-level resistance and cross-resistance to related drugs, while simultaneously resulting in collateral sensitivity towards other antimicrobial agents. This study also highlights that the evolution of high-level resistance towards ciprofloxacin significantly alters the production of secondary metabolites and cellular morphology. Furthermore, we identify mutations in regulatory and metabolic genes that result in enhanced efflux pump activation, advancing our understanding of the molecular mechanisms underlying high-level resistance. This study thus highlights the complex interplay between antibiotic resistance, metabolism, and morphological development.
Open AccessAdaptive Laboratory Evolution under gradual ciprofloxacin stress leads to efflux-mediated ciprofloxacin resistance and an increase in endogenous antibiotic production in Streptomyces coelicolor
Streptomyces are soil-dwelling bacteria harboring a vast reservoir of transcriptionally silent antibiotic-resistant genes. Mobilization of these resistance genes to pathogens results in the dissemination of multidrug resistance when exposed to differential antibiotic pressure. To determine the evolution of resistance, we employed adaptive laboratory evolution (ALE) in Streptomyces coelicolor under gradually increasing concentrations of ciprofloxacin, starting at the minimum inhibitory concentration (MIC) to 4X MIC. The evolved strain CipRr exhibited elevated resistance towards ciprofloxacin with cross-resistance to other fluoroquinolones, such as ofloxacin and moxifloxacin, and collateral sensitivity to the protein synthesis inhibitors chloramphenicol and tetracycline. Compared to the WT cells, CipRr showed elevated production of secondary metabolites actinorhodin and undecylprodigiosin, altered morphology, and reduced ROS production. Whole Genome Sequencing revealed mutations in transcriptional regulators and other metabolic genes, leading to enhanced activity of efflux pumps that conferred high-level ciprofloxacin resistance. Overall, this study demonstrates that evolutionary strategies in antibiotic producers such as streptomyces can help uncover the genetic determinants linked to antibiotic resistance, secondary metabolism, and morphological differentiation. Importance: This study employs adaptive laboratory evolution in the antibiotic-producing bacterium Streptomyces coelicolor to investigate how exposure to gradually increasing concentrations of the fluoroquinolone ciprofloxacin drives the emergence of high-level resistance and cross-resistance to related drugs, while simultaneously resulting in collateral sensitivity towards other antimicrobial agents. This study also highlights that the evolution of high-level resistance towards ciprofloxacin significantly alters the production of secondary metabolites and cellular morphology. Furthermore, we identify mutations in regulatory and metabolic genes that result in enhanced efflux pump activation, advancing our understanding of the molecular mechanisms underlying high-level resistance. This study thus highlights the complex interplay between antibiotic resistance, metabolism, and morphological development.
- 17 December 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (12) , e70163
Genome Amplification and Altered Transcriptome Aid in Survival and Enhanced Protein Secretion in Tunicamycin‐Resistant CHOK1 Cells
Chinese Hamster Ovary (CHO) cells are the predominant host for the production of biotherapeutics; however, there remains considerable potential to further enhance their cellular productivity. Adaptive laboratory evolution (ALE) combined with omics‐based analysis has emerged as a promising approach toward generating host cell lines with desirable characteristics. In this study, CHOK1 cells were gradually adapted to tunicamycin (TM), an endoplasmic reticulum (ER) stressor, resulting in an 8‐fold increase in resistance compared to the non‐adapted cells with a marked enlargement of the ER. Notably, the per‐cell secretion rate of total protein was 3‐ to 4‐fold higher in the TM‐adapted cells. Transcriptomic analysis revealed upregulation of several genes in the protein processing pathway, such as Dpagt1, the TM target gene, and ER stress response genes. The protein transport, secretion and ubiquitination pathways were also altered, potentially contributing to the increased protein secretion. Furthermore, genes participating in signaling cascades of PI3K‐AKT, MAPK, and Ras pathways were differentially expressed, thereby aiding in its survival and proliferation. Whole genome sequencing confirmed the amplification of a large genome segment of chromosome 4, which included several genes upregulated at the mRNA level, including Dpagt1. Thus, the survival and increased protein secretion of TM‐adapted cells can be attributed to a combination of transcriptional level changes and amplification of a large genome segment. Further, transient expression of a recombinant protein, SEAP, in TM‐adapted cells showed an improvement in specific productivity of ∼1.4 fold as compared to the non‐adapted cells, underscoring the importance of ALE as a cell engineering strategy.
- 17 December 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (12) , e70163
Genome Amplification and Altered Transcriptome Aid in Survival and Enhanced Protein Secretion in Tunicamycin‐Resistant CHOK1 Cells
Chinese Hamster Ovary (CHO) cells are the predominant host for the production of biotherapeutics; however, there remains considerable potential to further enhance their cellular productivity. Adaptive laboratory evolution (ALE) combined with omics‐based analysis has emerged as a promising approach toward generating host cell lines with desirable characteristics. In this study, CHOK1 cells were gradually adapted to tunicamycin (TM), an endoplasmic reticulum (ER) stressor, resulting in an 8‐fold increase in resistance compared to the non‐adapted cells with a marked enlargement of the ER. Notably, the per‐cell secretion rate of total protein was 3‐ to 4‐fold higher in the TM‐adapted cells. Transcriptomic analysis revealed upregulation of several genes in the protein processing pathway, such as Dpagt1, the TM target gene, and ER stress response genes. The protein transport, secretion and ubiquitination pathways were also altered, potentially contributing to the increased protein secretion. Furthermore, genes participating in signaling cascades of PI3K‐AKT, MAPK, and Ras pathways were differentially expressed, thereby aiding in its survival and proliferation. Whole genome sequencing confirmed the amplification of a large genome segment of chromosome 4, which included several genes upregulated at the mRNA level, including Dpagt1. Thus, the survival and increased protein secretion of TM‐adapted cells can be attributed to a combination of transcriptional level changes and amplification of a large genome segment. Further, transient expression of a recombinant protein, SEAP, in TM‐adapted cells showed an improvement in specific productivity of ∼1.4 fold as compared to the non‐adapted cells, underscoring the importance of ALE as a cell engineering strategy.
- Open Access
- 18 June 2025
- Published by Wiley
Genome Amplification and Altered Transcriptome aid in Survival and Enhanced Protein Secretion in Tunicamycin-Resistant CHOK1 cells
Chinese Hamster Ovary (CHO) cells are the predominant host for the production of biotherapeutics; however, there remains a considerable potential to further enhance their cellular productivity. Adaptive laboratory evolution (ALE) combined with omics-based analysis has emerged as a promising approach towards generating host cell lines with desirable characteristics. In this study, CHOK1 cells were gradually adapted to tunicamycin (TM), an endoplasmic reticulum (ER) stressor, resulting in an 8-fold increase in resistance compared to the non-adapted cells. Notably, a 3 to 4-fold increase was seen in the amount of total secreted protein in the TM-adapted cells. Transcriptomic analysis revealed upregulation of several genes in the protein processing pathway, such as Dpagt1, the TM target gene, and ER stress response genes. The protein transport, secretion and ubiquitination pathways were also altered, potentially contributing to the increased protein secretion. Furthermore, genes participating in signalling cascades of PI3K-AKT, MAPK and Ras pathways were differentially expressed, thereby aiding in its survival and proliferation. Whole genome sequencing confirmed the amplification of a large genome segment of chromosome 4, which included several genes upregulated at the mRNA level, including Dpagt1. However, overexpression of the Dpagt1 gene alone in the non-adapted cells did not replicate the phenotype of TM-adapted cells, signifying the role of other genes present in the amplified region. Thus, the survival and increased protein secretion of TM-adapted cells can be attributed to a combination of transcriptional level changes and amplification of a large genome segment, underscoring the importance of ALE as a cell engineering strategy.
- 18 June 2025
- Published by Wiley
Open AccessGenome Amplification and Altered Transcriptome aid in Survival and Enhanced Protein Secretion in Tunicamycin-Resistant CHOK1 cells
Chinese Hamster Ovary (CHO) cells are the predominant host for the production of biotherapeutics; however, there remains a considerable potential to further enhance their cellular productivity. Adaptive laboratory evolution (ALE) combined with omics-based analysis has emerged as a promising approach towards generating host cell lines with desirable characteristics. In this study, CHOK1 cells were gradually adapted to tunicamycin (TM), an endoplasmic reticulum (ER) stressor, resulting in an 8-fold increase in resistance compared to the non-adapted cells. Notably, a 3 to 4-fold increase was seen in the amount of total secreted protein in the TM-adapted cells. Transcriptomic analysis revealed upregulation of several genes in the protein processing pathway, such as Dpagt1, the TM target gene, and ER stress response genes. The protein transport, secretion and ubiquitination pathways were also altered, potentially contributing to the increased protein secretion. Furthermore, genes participating in signalling cascades of PI3K-AKT, MAPK and Ras pathways were differentially expressed, thereby aiding in its survival and proliferation. Whole genome sequencing confirmed the amplification of a large genome segment of chromosome 4, which included several genes upregulated at the mRNA level, including Dpagt1. However, overexpression of the Dpagt1 gene alone in the non-adapted cells did not replicate the phenotype of TM-adapted cells, signifying the role of other genes present in the amplified region. Thus, the survival and increased protein secretion of TM-adapted cells can be attributed to a combination of transcriptional level changes and amplification of a large genome segment, underscoring the importance of ALE as a cell engineering strategy.
- 3 July 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (8) , 2623-2636
Conserved Evolutionary Trajectory Can Be Perturbed to Prevent Resistance Evolution under Norfloxacin Pressure by Forcing Mycobacterium smegmatis on Alternate Evolutionary Paths
Antibiotic resistance is a pressing health issue, with the emergence of resistance in bacteria outcompeting the discovery of novel drug candidates. While many studies have used Adaptive Laboratory Evolution (ALE) to understand the determinants of resistance, the influence of the drug dosing profile on the evolutionary trajectory remains understudied. In this study, we employed ALE on Mycobacterium smegmatis exposed to various concentrations of Norfloxacin using both cyclic constant and stepwise increasing drug dosages to examine their impact on the resistance mechanisms selected. Mutations in an efflux pump regulator, LfrR, were found in all of the evolved populations irrespective of the drug profile and population bottleneck, indicating a conserved efflux-based resistance mechanism. This mutation appeared early in the evolutionary trajectory, providing low-level resistance when present alone, with a further increase in resistance resulting from successive accumulation of other mutations. Notably, drug target mutations, similar to those observed in clinical isolates, were only seen above a threshold of greater than 4x the minimum inhibitory concentration (MIC). A combination of three mutations in the genes, lfrR, MSMEG_1959, and MSMEG_5045, was conserved across multiple lineages, leading to high-level resistance and preceding the appearance of drug target mutations. Interestingly, in populations evolved from parental strains lacking the lfrA efflux pump, the primary target of the lfrR regulator, no lfrR gene mutations are selected. Furthermore, evolutional trajectories originating from the Delta lfrA strain displayed early arrest in some lineages and the absence of target gene mutations in those that evolved, albeit delayed. Thus, blocking or inhibiting the expression of efflux pumps can arrest or delay the fixation of drug target mutations, potentially limiting the maximum attainable resistance levels.
- 3 July 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (8) , 2623-2636
Conserved Evolutionary Trajectory Can Be Perturbed to Prevent Resistance Evolution under Norfloxacin Pressure by Forcing Mycobacterium smegmatis on Alternate Evolutionary Paths
Antibiotic resistance is a pressing health issue, with the emergence of resistance in bacteria outcompeting the discovery of novel drug candidates. While many studies have used Adaptive Laboratory Evolution (ALE) to understand the determinants of resistance, the influence of the drug dosing profile on the evolutionary trajectory remains understudied. In this study, we employed ALE on Mycobacterium smegmatis exposed to various concentrations of Norfloxacin using both cyclic constant and stepwise increasing drug dosages to examine their impact on the resistance mechanisms selected. Mutations in an efflux pump regulator, LfrR, were found in all of the evolved populations irrespective of the drug profile and population bottleneck, indicating a conserved efflux-based resistance mechanism. This mutation appeared early in the evolutionary trajectory, providing low-level resistance when present alone, with a further increase in resistance resulting from successive accumulation of other mutations. Notably, drug target mutations, similar to those observed in clinical isolates, were only seen above a threshold of greater than 4x the minimum inhibitory concentration (MIC). A combination of three mutations in the genes, lfrR, MSMEG_1959, and MSMEG_5045, was conserved across multiple lineages, leading to high-level resistance and preceding the appearance of drug target mutations. Interestingly, in populations evolved from parental strains lacking the lfrA efflux pump, the primary target of the lfrR regulator, no lfrR gene mutations are selected. Furthermore, evolutional trajectories originating from the Delta lfrA strain displayed early arrest in some lineages and the absence of target gene mutations in those that evolved, albeit delayed. Thus, blocking or inhibiting the expression of efflux pumps can arrest or delay the fixation of drug target mutations, potentially limiting the maximum attainable resistance levels.
- Open Access
Insight into the regulatory mechanism of the MFS transporter, SCO4121 by the MarR regulator, SCO4122
MarR group of transcriptional regulators are ubiquitous in bacteria and found to be involved in regulation of efflux pumps that confer multidrug resistance phenotype. While most characterized MarR regulators act as transcriptional repressors, we earlier identified a MarR regulator SCO4122 in Streptomyces coelicolor , playing an essential role in transcriptional activation of the MFS transporter SCO4121 in response to multiple substrates of the latter, including streptomycin, ciprofloxacin and chloramphenicol. In this study, using Surface Plasmon Resonance, we demonstrate that SCO4122 interacts directly with the diverse substrates of SCO4121 with the highest affinity for streptomycin with a KD of 0.73 μM. Further, in-vitro and in-vivo studies reveal that SCO4122 also binds to the intergenic region between sco4121 and sco4122, where the interaction is dependent on the cooperative binding of SCO4122 to three motifs in this region. A conserved Methionine, M93, in SCO4122 is identified to be an integral amino acid residue that is involved in activation of SCO4121 in response to ciprofloxacin, streptomycin and EtBr but not chloramphenicol. Furthermore, our studies also indicate that upon binding to different substrates, the affinity of SCO4122 to the sco4121 promoter increases 50-1000 fold, thereby leading to enhanced expression of the transporter, SCO4121. This study thus highlights that SCO4122 is a novel MarR regulator that functions as a strong transcriptional activator of an efflux pump, SCO4121, through intricate molecular mechanisms in presence of structurally dissimilar substrates. Graphical
Open AccessInsight into the regulatory mechanism of the MFS transporter, SCO4121 by the MarR regulator, SCO4122
MarR group of transcriptional regulators are ubiquitous in bacteria and found to be involved in regulation of efflux pumps that confer multidrug resistance phenotype. While most characterized MarR regulators act as transcriptional repressors, we earlier identified a MarR regulator SCO4122 in Streptomyces coelicolor , playing an essential role in transcriptional activation of the MFS transporter SCO4121 in response to multiple substrates of the latter, including streptomycin, ciprofloxacin and chloramphenicol. In this study, using Surface Plasmon Resonance, we demonstrate that SCO4122 interacts directly with the diverse substrates of SCO4121 with the highest affinity for streptomycin with a KD of 0.73 μM. Further, in-vitro and in-vivo studies reveal that SCO4122 also binds to the intergenic region between sco4121 and sco4122, where the interaction is dependent on the cooperative binding of SCO4122 to three motifs in this region. A conserved Methionine, M93, in SCO4122 is identified to be an integral amino acid residue that is involved in activation of SCO4121 in response to ciprofloxacin, streptomycin and EtBr but not chloramphenicol. Furthermore, our studies also indicate that upon binding to different substrates, the affinity of SCO4122 to the sco4121 promoter increases 50-1000 fold, thereby leading to enhanced expression of the transporter, SCO4121. This study thus highlights that SCO4122 is a novel MarR regulator that functions as a strong transcriptional activator of an efflux pump, SCO4121, through intricate molecular mechanisms in presence of structurally dissimilar substrates. Graphical